Zealthy is partly safe and partly worrying
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
1, with 80 percent of those members taking it for weight loss
TrimRx bills its flat plan price directly, without a separate membership layer to track
Additionally, the development of predictive tools and biomarkers that can guide treatment selection and adjustment is seen as a promising area for enhancing personalized care
Noom Med builds on the comprehensive Noom program by addressing biological barriers to weight loss with breakthrough medications like GLP-1s and clinician support